Payment overview · 2025
General Payments
$506.80
28 reported records · 8 companies
Healthcare provider profile · identity verified
Natalie Carter
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GUN BARREL CITY, TX · NPI 1659743482
Verified facts
What the public records show
CMS Open Payments records show Natalie Carter received $506.80 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.29 | 26.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.37 | 24.7% | 8 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $89.00 | 17.6% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $58.03 | 11.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $39.64 | 7.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.30 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.25 | 2.8% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.92 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $506.80 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.29 | 10 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $89.00 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.34 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.34 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $58.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $53.03 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $39.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 81 |
| Lisinopril | Lisinopril | 240 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 64 |
| Gabapentin | Gabapentin | 159 | 54 |
| Meloxicam | Meloxicam | 158 | 45 |
| Metformin Hcl | Metformin Hcl | 150 | 46 |
| Losartan Potassium | Losartan Potassium | 147 | 48 |
| Trazodone Hcl | Trazodone Hcl | 144 | 43 |
| Alprazolam | Alprazolam | 141 | 28 |
| Sertraline Hcl | Sertraline Hcl | 138 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 32 |
| Furosemide | Furosemide | 111 | 42 |
| Montelukast Sodium | Montelukast Sodium | 105 | 26 |
| Azithromycin | Azithromycin | 99 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 46 |
| Prednisone | Prednisone | 94 | 69 |
| Simvastatin | Simvastatin | 89 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 13 |
| Potassium Chloride | Potassium Chloride | 87 | 29 |
| Omeprazole | Omeprazole | 85 | 27 |
| Allopurinol | Allopurinol | 84 | 17 |
| Estradiol | Estradiol | 83 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 24 |
| Bupropion Xl | Bupropion Hcl | 79 | 18 |
| Eliquis | Apixaban | 78 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 31 |
| Methocarbamol | Methocarbamol | 65 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 25 |
| Carvedilol | Carvedilol | 63 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 18 |
| Spironolactone | Spironolactone | 55 | 17 |
| Ezetimibe | Ezetimibe | 52 | 14 |
| Fluconazole | Fluconazole | 52 | 26 |
| Naproxen | Naproxen | 52 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | 15 |
| Ozempic | Semaglutide | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 16 |
| Amoxicillin | Amoxicillin | 46 | 38 |
| Ondansetron Odt | Ondansetron | 46 | 18 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 13 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Glipizide | Glipizide | 43 | 12 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Famotidine | Famotidine | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 11 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 11 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 15 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 12 |
| Progesterone | Progesterone, Micronized | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | 14 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $506.80 · 28 records | ABBVIE INC. | BREZTRI, Cologuard Collection Kit, JARDIANCE, Korlym, MOUNJARO, NP Thyroid 60, VRAYLAR, XYOSTED, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error